DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding.

Autor:	Zhao X; Gynecology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.; Jiangwan Research Institute, Central South University, Changsha, Hunan, China.; Postdoctoral Station of Clinical Medicine, the Third Xiangya Hospital, Central South University, Changsha, China., Yang Y; Gynecology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China., Fu Y; Gynecology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China., Lv W; Gynecology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China dabaoxu2022@163.com lvweigang@sklmg.edu.cn., Xu D; Gynecology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China dabaoxu2022@163.com lvweigang@sklmg.edu.cn.
Jazyk:	angličtina
Zdroj:	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Aug 05; Vol. 34 (8), pp. 1165-1171. Date of Electronic Publication: 2024 Aug 05.
DOI:	10.1136/ijgc-2024-005723
Abstrakt:	Objective: The aim of our study was to explore the value of DNA (CDO1m/CELF4m) methylation detection in exfoliated cervical cells collected for screening endometrial cancer in premenopausal women with abnormal uterine bleeding. Methods: A total of 296 premenopausal women with abnormal uterine bleeding admitted to the Department of Obstetrics and Gynecology at the Third Xiangya Hospital of Central South University from November 2021 to October 2022 were selected. Clinical characteristics, endometrial thickness measured by transvaginal ultrasound and serum CA125 were collected. Exfoliated cervical cells from the thinPrep cytogic test were collected for DNA (CDO1m/CELF4m) methylation testing. Endometrial tissue was collected under hysteroscopy for pathological diagnosis as the gold standard. A univariate logistic regression model was used to analyze risk factors for endometrial cancer. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to measure the diagnostic efficacy of DNA methylation detection in endometrial cancer screening of women with abnormal uterine bleeding. Results: Univariate logistic regression analysis showed that age, body mass index (BMI) ≥25 kg/m 2 , endometrial thickness ≥11 mm, CDO1 methylation (CDO1mΔCt≤8.4), CELF4 methylation (CELF4mΔCt≤8.8), and dual gene methylation (CDO1mΔCt≤8.4 or CELF4mΔCt≤8.8) were independent risk factors for endometrial cancer in women with abnormal uterine bleeding. The odds ratio (OR) values (95% confidence interval (CI) were 0.87 (0.80-0.95), 4.76 (1.89-11.96), 8.41 (3.13-22.59), 64.49 (20.46-203.33), 12.79 (4.91-33.30), and 42.53 (11.90-152.04), respectively. Among these indicators, dual gene methylation had the higher sensitivity and specificity for endometrial cancer screening (85.7% and 87.6%). Moreover, dual gene methylation combined with BMI or endometrial thickness could further improve the screening efficiency of endometrial cancer in women with abnormal uterine bleeding. Conclusions: In premenopausal women with abnormal uterine bleeding, the clinical efficacy of DNA (CDO1m/CELF4m) methylation detection in exfoliated cervical cells for endometrial cancer screening was better than that of other noninvasive clinical indicators. In addition, dual gene methylation combined with BMI or endometrial thickness was a good predictor of endometrial cancer screening. Competing Interests: Competing interests: None declared. (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu